HELX ETF
Franklin Genomic Advancements ETF
HELX ETF Overview
HELX ETF (Franklin Genomic Advancements ETF) is managed by Franklin Templeton Investments (US) with $31.5M in net assets. HELX expense ratio is 0.50%, holding 69 positions across sectors including Health Care, Information Technology, Materials. Inception date: 2020-02-25.
HELX performance shows a YTD return of 6.27%. The 1-year return is 40.32% and the 5-year return is -5.97%.
HELX top holdings include Guardant Health, Inc (9.1%), Natera Inc (8.4%), Krystal Biotech Inc (5.8%), Adaptive Biotechnologies Corp (4.4%), Ligand Pharmaceuticals, Inc. (4.3%). Go to all HELX holdings, HELX sectors, or HELX dividends.
HELX can be compared against other funds. Use HELX overlap to find shared positions, or HELX vs another fund for a side-by-side view. HELX alternatives are available via the screener, along with tax-loss harvesting opportunities.